Search results
PROMOTED
Author(s):
Nicolas M Van Mieghem
,
Kendra J Grubb
,
David Hildick-Smith
,
et al
Start date:
Mar 26, 2024
Editorial
Author(s):
Angela Hoye
Added:
3 years ago
Article
Author(s):
Mohammad Sahebjalal
,
Nick Curzen
Added:
3 years ago
Antiplatelet therapy (APT) represents a major cornerstone in the secondary prevention of coronary artery disease, along with modifying patients’ risk factors. Furthermore, it has been clear, since early unsuccessful regimens, including warfarin and dypiridamole with aspirin, that it is APT that stops coronary stents from clotting off and causing stent thrombosis.1,2 Specifically, the requirement…
View more
Author(s):
Kevin S Tang
,
Shoujit Banerjee
,
George Tang
,
et al
Added:
3 months ago
Author(s):
Azfar Zaman
,
Bernard Prendergast
,
David Hildick-Smith
,
et al
Added:
11 months ago
Author(s):
Dean J Kereiakes
Added:
4 years ago
Prof Dean J Kereiakes (The Lindner Research Center at The Christ Hospital, Cincinnati, OH, US) co-principal investigator of the DAPT Study, discusses the effectiveness of short-term DAPT in the prevention of stent thrombosis following stent implantation.
Questions:
1. How does the duration of DAPT affect clinical outcomes?
2. Why is there a debate about DAPT duration?
3. What is the clinical…
View more
Author(s):
Neil Ruparelia
Added:
3 years ago
Transcatheter aortic valve implantation (TAVI) is now the accepted treatment option of choice for patients presenting with severe symptomatic aortic stenosis who are deemed to be inoperable or of high surgical risk.1,2 Short- and intermediate-term outcomes have been promising3–5 and with increasing institutional and operator experience combined with technological advancements there has been…
View more
Author(s):
Jean-Philippe Collet
Added:
3 years ago
The role of platelets in coronary artery thrombosis is well-established.1 They also play a critical role in a number of cardiovascular conditions including stroke, peripheral vascular disease and diabetes, and may be involved in the pathology underlying atherosclerotic changes.1 Antiplatelet agents such as clopidogrel, a platelet P2Y12 receptor antagonist, and aspirin are used for the prevention…
View more
Author(s):
Roxana Mehran
,
Pascal Vranckx
,
Marco Valgimigli
,
et al
Added:
1 year ago
This broadcast series 'Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?'will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.
The third broadcast in this series, focused onBalancing Risk Post-PCI.In this on-demand version of…
View more
AF, Stent and Anticoagulant
Author(s):
Balen Abdulrahman
,
Richard J Jabbour
,
Nick Curzen
Added:
9 months ago
Article